# A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects

> **NCT01916174** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 50 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2
- Healthy

## Interventions

- **DRUG:** insulin degludec/liraglutide
- **DRUG:** insulin degludec/liraglutide

## Key facts

- **NCT ID:** NCT01916174
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2013-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01916174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01916174, "A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01916174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*